Actively Recruiting
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Led by Mayo Clinic · Updated on 2026-02-06
100
Participants Needed
1
Research Sites
371 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.
CONDITIONS
Official Title
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients with hormone receptor-positive metastatic breast cancer
- Pre- or post-menopausal women
- Patients scheduled to start or currently receiving FDA-approved CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) with endocrine therapy
- Patients scheduled to start or currently receiving FDA-approved endocrine therapy alone
- Patients meeting eligibility for any listed therapy groups who can co-enroll if already in another clinical trial
You will not qualify if you...
- Patients receiving investigational agents or experimental therapies
- Patients with early breast cancer diagnosis
- Male breast cancer patients
- Patients currently treated for other active cancers except nonmelanoma skin cancer or carcinoma-in-situ
- Patients unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here